CGT PROJECT| Pharma.Aero publishes WP1 Industry Paper on the Cell and Gene Therapy Market and Logistics

With the first work package (WP1) of the Cell and Gene Therapy Project completed, Pharma.Aero is sharing the main findings together with relevant aspects identified as being important in the transportation process (current capabilities, constraints, and challenges).

Check the WP1 Industry Paper here to find out what are the fundamental CGT particularities that have a great influence in determining the logistic solutions:

🔹Market Overview 🔹Logistics and Supply Chain 🔹Key Logistics Challenges 🔹Other Airfreight Specific Challenges

The CGT places significant challenges on the current clinical and commercial supply chain. The logistic sector needs to collaborate directly with researchers and manufacturers to understand the specific needs, and demands of the CGT products, and define together the solutions for safe and efficient transportation.

The CGT’s sector presents unique complexity in terms of supply chain and logistics flows. Challenges are found in every link of the chain, from planning, and procurement to distribution, and require simultaneous shipments at different temperatures. The global challenges of the sector including cost control and industry standardization are subject to a lot of reflection and request significant improvements at the logistics level.

In this context, air transport is an essential link in the logistical chain and represents a key element on which to capitalize to make flows more fluid. It is important to encourage greater collaboration in the industry to facilitate logistical improvements necessary for CGT.